Search Result

Results for "

kidney cancer

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Apoptosis (17) Aquaporin (1) Atg8/LC3 (2) Autophagy (7) Bcl-2 Family (3) c-Met/HGFR (1) c-Myc (1) Cadherin (1) Calcium Channel (2) Caspase (4) CDK (2) COX (1) Cytochrome P450 (1) Drug Metabolite (1) E1/E2/E3 Enzyme (1) Endogenous Metabolite (5) ERK (2) Ferroptosis (4) Fungal (2) FXR (2) Glutaminase (1) GSK-3 (1) HDAC (1) HIF/HIF Prolyl-Hydroxylase (2) HSV (2) iGluR (2) Interleukin Related (1) Isotope-Labeled Compounds (1) Liposome (1) MDM-2/p53 (1) Microtubule/Tubulin (1) Mitophagy (3) MMP (2) Na+/K+ ATPase (2) NADPH Oxidase (1) Necroptosis (2) NEKs (1) NF-κB (3) Nucleoside Antimetabolite/Analog (1) Opioid Receptor (3) p38 MAPK (3) p62 (2) Parasite (2) PARP (2) Phosphatase (2) PI3K (4) PINK1/Parkin (3) PKA (1) PPAR (1) PSMA (1) Pyruvate Kinase (1) Ras (2) Reactive Oxygen Species (ROS) (6) Reference Standards (7) RET (1) ROS Kinase (1) SHP1 (2) SHP2 (2) Src (2) Syk (2) Tau Protein (1) TGF-beta/Smad (2) TGF-β Receptor (3) TNF Receptor (3) Topoisomerase (3) Transmembrane Glycoprotein (1) VD/VDR (1) VEGFR (2)
By Research Areas:	Cancer (38) Cardiovascular Disease (12) Endocrinology (2) Infection (4) Inflammation/Immunology (15) Metabolic Disease (7) Neurological Disease (9)
Oligonucleotides:	Fillers (1)

Inhibitors & Agonists

Screening Libraries

MCE Kits

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: BCRP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-157395

malonyl-NAC	Pyruvate Kinase	Cancer
malonyl-NAC increases cellular propylation, resulting in reduced endogenous GAPDH activity. malonyl-NAC increases GAPDH malonylation in cells and inhibits pyruvate kinase activity. In addition, malonyl-NAC limits the metabolism and proliferation of a highly glycolytic kidney cancer cell line harboring a tricarboxylic acid cycle mutation .

HY-N0164

Matrine Maximum Cited Publications 16 Publications Verification Matridin-15-one; Vegard; α-Matrine	PINK1/Parkin Opioid Receptor Autophagy Mitophagy Ferroptosis Apoptosis	Inflammation/Immunology Cancer
Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus that can act as a kappa opioid receptor and u-receptor agonist. Matrine has a variety of pharmacological effects, including anti-cancer, anti-oxidative stress, anti-inflammation and anti-apoptosis effects. Matrine is potential in the research of disease like human non-small cell lung cancer, hepatoma, papillary thyroid cancer and acute kidney injury (AKI) .

HY-P2997

γ-glutamyltransferase, Porcine kidney 1 Publications Verification GGT, Porcine kidney	Endogenous Metabolite	Cancer
γ-glutamyltransferase, Porcine kidney (GGT, Porcine kidney) is an enzyme located on the outer surface of the cell membrane. γ-glutamyltransferase, Porcine kidney maintains the physiological concentration of cytoplasmic glutathione and the cell's defense against oxidative stress by cleaving extracellular glutathione and increasing the availability of amino acids. γ-glutamyltransferase, Porcine kidney is used for pancreatic cancer research .

HY-150076

BLU2864	PKA	Metabolic Disease Cancer
BLU2864 is an orally active, highly selective, ATP-competitive PRKACA inhibitor (IC₅₀=0.3 nM). BLU2864 shows anti-tumor activity. BLU2864 can be used in cancer and polycystic kidney disease research .

HY-120929

BI8622 4 Publications Verification	E1/E2/E3 Enzyme c-Myc	Inflammation/Immunology Cancer
BI8622 is a specific inhibitor of the ubiquitin ligase HUWE1 with an IC₅₀ of 3.1 μM. BI8622 can decrease the protein expression levels of c-myc and glycolytic markers as well as immune modulatory markers after HUWE1 inhibition in triple-negative breast cancer (TNBC) cell lines. BI8622 significantly protects against cisplatin (HY-17394)-induced acute kidney injury (AKI). BI8622 significantly reduces the growth of multiple myeloma (MM) cell lines and induces cell cycle arrest. BI8622 can prevent HUWE1-dependent TTBK2 ubiquitination. BI8622 can be studied in research for various diseases including medulloblastoma, acute kidney injury, breast cancer and MM .

HY-163629

Anticancer agent 224	Others	Cancer
Anticancer agent 224 (Compound 16) is an anticancer agent that can effectively inhibit the growth of central nervous system (CNS), kidney and breast cancer cell, with a GI₅₀ value ranging from 0.6 to 12.8 μM .

HY-155249

KGP591	Microtubule/Tubulin	Cancer
KGP591 is a tubulin polymerization inhibitor (IC₅₀ 0.57 µM). KGP591 induces significant G2/M stagnation, inhibits cell migration, disrupts microtubule structure and cell morphology in MDA-MB-231 cells. KGP591 shows antitumor activity in orthotopic model of kidney cancer (RENCA) .

HY-N0164R

Matrine (Standard) Matridin-15-one (Standard); Vegard (Standard); α-Matrine (Standard)	PINK1/Parkin Reference Standards Opioid Receptor Autophagy Mitophagy Ferroptosis Apoptosis	Inflammation/Immunology Cancer
Matrine (Standard) is the analytical standard of Matrine. This product is intended for research and analytical applications. Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus that can act as a kappa opioid receptor and u-receptor agonist. Matrine has a variety of pharmacological effects, including anti-cancer, anti-oxidative stress, anti-inflammation and anti-apoptosis effects. Matrine is potential in the research of disease like human non-small cell lung cancer, hepatoma, papillary thyroid cancer and acute kidney injury (AKI) .

HY-101284A

(E/Z)-DMU2105	Cytochrome P450	Cancer
(E/Z)-DMU2105 (Compound 7k) is a potent and highly selective CYP1B1 inhibitor. (E/Z)-DMU2105 inhibits human CYP1B1 enzyme bound to yeast-derived microsomes with an IC₅₀ value of 10 nM. (E/Z)-DMU2105 also potently inhibits CYP1B1 expressed within ‘live’ recombinant yeast and human HEK293 kidney cells with an IC₅₀ value of 63.65 nM. (E/Z)-DMU2105 can be used for the research of cancer, glaucoma, ischemia and obesity .

HY-147971

Anticancer agent 75	Parasite Topoisomerase	Infection Cancer
Anticancer agent 75 is a potent anticancer agent. Anticancer agent 75 shows cytotoxicity and selectivity in cancer cell lines. Anticancer agent 75 shows cytotoxicity to normal human kidney cell lines is at least 35 times lower than that of the Doxorubicin standard. Anticancer agent 75 shows good activity of antiplasmodial .

HY-143546

RET-IN-9	RET	Cancer
RET-IN-9 is a potent inhibitor of RET. RET kinase is a single-pass transmembrane receptor tyrosine kinase that plays an important role in the development of the kidney and enteric nervous system, and the maintenance of homeostasis in the nervous, endocrine, hematopoietic, and male reproductive systems. RET-IN-9 has the potential for the research of RET-related disease including non-small cell lung cancer and medullary thyroid cancer (extracted from patent WO2021115457A1, compound 29) .

HY-N2013

Aristolactam I 1 Publications Verification Aristololactam; Aristolactam	Drug Metabolite Aquaporin Cadherin TGF-beta/Smad	Endocrinology Cancer
Aristolactam I is an AQP1 inhibitor and Aristolochic acid I metabolite. Aristolactam I can be isolated from Aristolochia plants. Aristolactam I downregulates Twist1 expression, increases E-cadherin expression, and activates the TGF-β/Smad signaling pathway. Aristolactam I has anticancer activity against breast cancer. Aristolactam I is nephrotoxic. Aristolactam I is mainly used in the study of breast cancer and kidney diseases such as renal interstitial fibrosis .

HY-163074

Ferroptosis-IN-6	Ferroptosis	Cancer
Ferroptosis-IN-6 (compound 13) is a potent inhibitor of Ferroptosis with EC₅₀ of 25.5 nM. Ferroptosis-IN-6 significantly inhibits RSL3-induced cell death in cells and in vivo .

HY-144425

BSc5367	NEKs	Inflammation/Immunology
BSc5367 is a potent Nek1 inhibitor with an IC₅₀ of 11.5 nM. NIMA-related protein kinase Nek1 is crucially involved in cell cycle regulation, DNA repair and microtubule regulation and dysfunctions of Nek1 play key roles in amyotrophic lateral sclerosis (ALS), polycystic kidney disease (PKD) and several types of radiotherapy resistant cancer .

HY-W654256

Matrine-d3 Matridin-15-one-d₃; Vegard-d₃; α-Matrine-d₃	Isotope-Labeled Compounds PINK1/Parkin Opioid Receptor Autophagy Mitophagy Ferroptosis Apoptosis	Inflammation/Immunology Cancer
Matrine-d₃ (Matridin-d₃) is a deuterium labeled Matrine (HY-N0164). Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus that can act as a kappa opioid receptor and u-receptor agonist. Matrine has a variety of pharmacological effects, including anti-cancer, anti-oxidative stress, anti-inflammation and anti-apoptosis effects. Matrine is potential in the research of disease like human non-small cell lung cancer, hepatoma, papillary thyroid cancer and acute kidney injury (AKI) .

HY-152479

Topoisomerase IIα-IN-7	Topoisomerase	Cancer
Topoisomerase IIα-IN-7 is an DNA topoisomerase IIα inhibitor with an IC₅₀ value of 7.7 µM. Topoisomerase IIα-IN-7 has broad-spectrum cytotoxicity to leukemia, lung, colon, melanoma, ovarian, kidney, prostate and breast cancer cells. Topoisomerase IIα-IN-7 has metabolic stability .

HY-18260

Bisphenol A 5+ Cited Publications	Endogenous Metabolite p38 MAPK Akt Reactive Oxygen Species (ROS) Apoptosis	Cardiovascular Disease Metabolic Disease Endocrinology Cancer
Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cancers, cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders .

HY-156527

PHD-IN-2	HIF/HIF Prolyl-Hydroxylase	Cancer
PHD-IN-2 (Compound 91) is a PHD antagonist (IC₅₀: < 5 nM). PHD-IN-2 induces erythropoietin synthesis in HEP3B cells (EC₅₀: <2.5 μM). PHD-IN-2 can be used for research of cardiovascular disorders, metabolic disorders, hematological disorders, pulmonary disorders, kidney disorders, liver disorders, wound healing disorders, and cancer .

HY-158378

Trivalent hydroxyarsinothricn R-AST-OH	Glutaminase	Cancer
Trivalent hydroxyarsinothricn (R-AST-OH) is a covalent and irreversible kidney-type glutaminase (KGA) inhibitor. Trivalent hydroxyarsinothricn binds to the glutamine binding site and forms a covalent bond with an active site cysteine residue. Trivalent hydroxyarsinothricn selectively kills triple-negative breast cancer (TNBC) cells and is not cytotoxic to the control cell line. KGA is the enzyme that controls glutamine metabolism and is correlated with tumor malignancy .

HY-Y1117

Melamine 1 Publications Verification	Apoptosis TGF-β Receptor NF-κB COX NADPH Oxidase ROS Kinase	Neurological Disease Inflammation/Immunology
Melamine is an orally active inducer of Apoptosis. Melamine induces animal disease models. Melamine affects the activity of Sertoli cell and can be used for research on male reproductive function. Melamine also has neurotoxicity and nephrotoxicity. Melamine induces cognitive impairment and acute kidney injury models. Melamine can also be used to induce bladder cancer and urinary stone models .

HY-P991565

CE-355621	c-Met/HGFR	Cancer
CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. CE-355621 can effectively bind with human c-Met (K_D = 200 pM, IC₅₀ = 466 pM) in A549 cells and cyno c-Met (K_D = 610 pM) in cynomolgus kidney cells. CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding. CE-355621 significantly inhibit the growth of tumors dependent on the c-Met/HGF pathway. CE-355621 can be used for research on cancer such as glioblastoma and gastric cancer .

HY-N2013R

Aristolactam I (Standard) Aristololactam (Standard); Aristolactam (Standard)	Reference Standards Caspase Apoptosis	Inflammation/Immunology
Aristolactam I (Standard) is the analytical standard of Aristolactam I. This product is intended for research and analytical applications. Aristolactam I is an AQP1 inhibitor and Aristolochic acid I metabolite. Aristolactam I can be isolated from Aristolochia plants. Aristolactam I downregulates Twist1 expression, increases E-cadherin expression, and activates the TGF-β/Smad signaling pathway. Aristolactam I has anticancer activity against breast cancer. Aristolactam I is nephrotoxic. Aristolactam I is mainly used in the study of breast cancer and kidney diseases such as renal interstitial fibrosis .

HY-N0805

Alisol B 23-acetate 1 Publications Verification 23-Acetylalismol B; 23-O-Acetylalisol B; Alisol B monoacetate	Apoptosis Reactive Oxygen Species (ROS) CDK MMP PARP FXR Syk	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Alisol B 23-acetate is an orally active prototerpane-type triterpenoid. Alisol B 23-acetate can be isolated from Alisma orientalis. Alisol B 23-acetate induces Apoptosis, promotes ROS generation, downregulates CDK4/6, MMP-2/9, upregulates cleaved PARP, activates FXR and inhibits Syk. Alisol B 23-acetate has anti-inflammatory and hepatoprotective activities. Alisol B 23-acetate protects the kidney from ischemia-reperfusion injury. Alisol B 23-acetate has anticancer activity against ovarian cancer, colon cancer, lung cancer, and gastric cancer. Alisol B 23-acetate can be used in the study of atherosclerosis and allergic asthma .

HY-129878

N-Trifluoroacetyladriamycin AD-41	Endogenous Metabolite	Cancer
N-Trifluoroacetyladriamycin (AD-41) is a chemotherapeutic compound with antitumor activity. N-Trifluoroacetyladriamycin exhibits the highest fluorescence and radioactivity levels in the small intestine and liver, indicating its significant accumulation in these tissues. N-Trifluoroacetyladriamycin also shows significant accumulation in the kidney, spleen, large intestine, lung, and heart. N-Trifluoroacetyladriamycin is a metabolite of Valrubicin, which is used to inhibit bladder cancer. The presence of N-Trifluoroacetyladriamycin and its derivatives may be related to the biotransformation of the compound and its antitumor mechanism .

HY-W010201R

Citronellol (Standard) 2 Publications Verification (±)-Citronellol (Standard); (±)-β-Citronellol (Standard)	Reactive Oxygen Species (ROS) Reference Standards ERK PI3K TNF Receptor Atg8/LC3 p62 Apoptosis Necroptosis Autophagy Fungal	Cardiovascular Disease Neurological Disease Cancer
Citronellol (Standard) is the analytical standard of Citronellol. Citronellol (Standard) is an orally active inducer of apoptosis. Citronellol (Standard) can prevent oxidative stress, mitochondrial dysfunction, and apoptosis in the SH-SY5Y cell Parkinson's disease model induced by 6-OHDA by regulating the ROS-NO, MAPK/ERK, and PI3K/Akt signaling pathways. Citronellol (Standard) can induce necroptosis in human lung cancer cells through the TNF-α pathway and accumulation of ROS. Citronellol (Standard) can reduce the levels of LC-3 and p62 to regulate the autophagy pathway, inhibit oxidative stress and neuroinflammation, and thus have neuroprotective effects on Parkinson's rats. Citronellol (Standard) exhibits anti-fungal activity against Trichophyton rubrum by inhibiting ergosterol synthesis .

HY-W010201

Citronellol 2 Publications Verification (±)-Citronellol; (±)-β-Citronellol	Reactive Oxygen Species (ROS) ERK PI3K TNF Receptor Atg8/LC3 p62 Apoptosis Necroptosis Autophagy Fungal	Cardiovascular Disease Neurological Disease Cancer
Citronellol ((±)-Citronellol) is an orally active inducer of apoptosis. Citronellol can prevent oxidative stress, mitochondrial dysfunction, and apoptosis in the SH-SY5Y cell Parkinson's disease model induced by 6-OHDA by regulating the ROS-NO, MAPK/ERK, and PI3K/Akt signaling pathways. Citronellol can induce necroptosis in human lung cancer cells through the TNF-α pathway and accumulation of ROS. Citronellol can reduce the levels of LC-3 and p62 to regulate the autophagy pathway, inhibit oxidative stress and neuroinflammation, and thus have neuroprotective effects on Parkinson's rats. Citronellol exhibits anti-fungal activity against Trichophyton rubrum by inhibiting ergosterol synthesis .

HY-P99020

Fresolimumab 1 Publications Verification GC1008	TGF-beta/Smad	Metabolic Disease Inflammation/Immunology Cancer
Fresolimumab (GC1008) is a human monoclonal antibody against TGF-β that neutralizes all mammalian active subtypes of TGF-β. The binding affinity of Fresolimumab to TGF-β2 is 1.8 nM. Fresolimumab improves Bleomycin (HY-108345)-induced acute lung injury. Fresolimumab radiolabeled with ⁸⁹Zr can be used for PET analysis of TGF-β expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease .

HY-N0805R

Alisol B 23-acetate (Standard) 23-Acetylalismol B (Standard); 23-O-Acetylalisol B (Standard); Alisol B monoacetate (Standard)	Reference Standards Apoptosis Reactive Oxygen Species (ROS) CDK MMP PARP FXR Syk	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Alisol B 23-acetate (Standard) is the analytical standard of Alisol B 23-acetate (HY-N0805). This product is intended for research and analytical applications. Alisol B 23-acetate is an orally active prototerpane-type triterpenoid. Alisol B 23-acetate can be isolated from Alisma orientalis. Alisol B 23-acetate induces Apoptosis, promotes ROS generation, downregulates CDK4/6, MMP-2/9, upregulates cleaved PARP, activates FXR and inhibits Syk. Alisol B 23-acetate has anti-inflammatory and hepatoprotective activities. Alisol B 23-acetate protects the kidney from ischemia-reperfusion injury. Alisol B 23-acetate has anticancer activity against ovarian cancer, colon cancer, lung cancer, and gastric cancer. Alisol B 23-acetate can be used in the study of atherosclerosis and allergic asthma .

HY-N0031

Plantamajoside 1 Publications Verification	NF-κB PI3K Akt Apoptosis Autophagy p38 MAPK Src	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Plantamajoside is an orally active phenylpropanoid glycoside. Plantamajoside can be isolated from Plantago asiatica L.(Plantaginaceae). Plantamajoside inactivates NF-κB, PI3K/akt, induces Apoptosis, and improves Autophagy. Plantamajoside regulates MAPK, integrin-linked kinase/c-Src. Plantamajoside inhibits multiple cancers, improves lung and kidney damage. Plantamajoside has neuroprotective and anti-inflammatory effects .

HY-175034

Topoisomerase I/II-IN-1	Topoisomerase Apoptosis MDM-2/p53 Bcl-2 Family Caspase	Cancer
Topoisomerase I/II-IN-1 is a dual inhibitor of topoisomerase I/II. Topoisomerase I/II-IN-1 induces G2/M arrest and apoptosis in cancer cells by upregulating p53, p21, and Bax mRNA levels, caspase-3 protein levels, and the Bax/Bcl-2 ratio, while downregulating Bcl-2. Topoisomerase I/II-IN-1 is useful in the study of various cancers, including melanoma, renal cancer, colorectal cancer, and breast cancer .

HY-W754025

Pre-vitamin D3 decanoate	VD/VDR	Others
Pre-vitamin D3 decanoate is a derivative of vitamin D3 that can be converted into the active form of vitamin D in the body. Pre-vitamin D3 decanoate is first converted to 25-hydroxyvitamin D3 in the liver and then further converted to 1,25-dihydroxyvitamin D3 in the kidneys. During preparation, vitamin D3 may react with the triglycerides in the formulation to form ester compounds, and this esterification affects the stability and bioavailability of vitamin D3. Pre-vitamin D3 decanoate can be used in the study of certain diseases associated with vitamin D, such as osteoporosis, autoimmune diseases, and certain cancers .

HY-121659

DCFBC	PSMA	Cancer
DCFBC is a prostate-specific membrane antigen (PSMA) inhibitor that can be used for small animal positron emission tomography (PET) imaging. DCFBC labeled with F ¹⁸ ([18F]DCFBC) can images in severe combined immunodeficient mice. [18F]DCFBC uptake is higher in PIP tumors, but almost absent in FLU tumors. [18F]DCFBC uptake is also high in the kidney and bladder, but the radioactivity washout time is shorter than that in PIP tumors. Indicating that [18F]DCFBC can specifically localize to PSMA+ expressing tumors and is applicable to the study of prostate cancer .

HY-W008344

2-Chloroadenosine	Nucleoside Antimetabolite/Analog Apoptosis	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
2-Chloroadenosine is an adenosine analog, a transporter permeabilizer of nucleoside transporters, and a competitive uridine influx inhibitor (apparent K_i=33 μM). 2-Chloroadenosine binds to nitrobenzylthioinosine with high affinity (apparent K_i=0.18 mM). 2-Chloroadenosine promotes Apoptosis and increases cerebral blood flow. 2-Chloroadenosine has anticonvulsant properties. 2-Chloroadenosine is used to study infection, inflammatory diseases, cancer, blood-related diseases, lung injury, epilepsy, and kidney disease .

HY-144332

PHD2/HDACs-IN-1	HDAC HIF/HIF Prolyl-Hydroxylase	Cancer
PHD2/HDACs-IN-1 is a potent PHD2/HDACs hybrid inhibitor (IC₅₀s of 1.15 μM, 19.75 μM, 26.60 μM and 15.98 μM for PHD2, HDAC1, HDAC2 and HDAC6, respectively). PHD2/HDACs-IN-1 is a low-toxicity renoprotective agent for research of cisplatin-induced acute kidney injury (AKI) .

HY-N0031R

Plantamajoside (Standard)	Reference Standards NF-κB PI3K Apoptosis Autophagy p38 MAPK Src	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Plantamajoside (Standard) is the analytical standard of Plantamajoside. This product is intended for use in research and analytical applications. Plantamajoside is an orally active phenylpropanoid glycoside. Plantamajoside can be isolated from Plantago asiatica L.(Plantaginaceae). Plantamajoside inactivates NF-κB, PI3K/akt, induces Apoptosis, and improves Autophagy. Plantamajoside regulates MAPK, integrin-linked kinase/c-Src. Plantamajoside inhibits multiple cancers, improves lung and kidney damage. Plantamajoside has neuroprotective and anti-inflammatory effects .

HY-N1472

Levistolide A 3 Publications Verification	Apoptosis Reactive Oxygen Species (ROS) PPAR GSK-3 Tau Protein Ras TGF-β Receptor	Infection Neurological Disease Inflammation/Immunology
Levistolide A is an apoptosis inducer and a PEDV virus inhibitor. Levistolide A can induce apoptosis in colon cancer cells and suppress the replication of porcine epidemic diarrhea virus (PEDV) by promoting ROS generation. Levistolide A activates peroxisome proliferator-activated receptor γ (PPARγ) in N2a/APP695swe cells and reduces excessive phosphorylation of tau through the GSK3α/β pathway, improving symptoms in Alzheimer’s mice. Levistolide A improves kidney damage in 5/6 nephrectomy (Nx) mice by inhibiting the RAS,TGF-β1/Smad, and MAPK pathways .

HY-125108

PHPS1 sodium 3 Publications Verification	SHP2 SHP1 Phosphatase	Cardiovascular Disease Cancer
PHPS1 sodium is a potent and selective Shp2 inhibitor with K_is of 0.73, 5.8, 10.7, 5.8, and 0.47 μM for Shp2, Shp2-R362K, Shp1, PTP1B, and PTP1B-Q, respectively .

HY-B1357R

Digitoxin (Standard)	Reference Standards Bcl-2 Family Caspase Apoptosis HSV Na+/K+ ATPase Calcium Channel	Cardiovascular Disease Cancer
Digitoxin (Standard) is the analytical standard of Digitoxin. This product is intended for research and analytical applications. Digitoxin is an anti-cancer agent. Digitoxin induces apoptosis, inhibits influenza cytokine storm, causes DNA double-stranded breaks (DSBs) and blocks the cell cycle at the G2/M phase. Digitoxin induces calcium uptake into cells by forming transmembrane calcium channels and can be used for research of heart failure .

HY-112368

PHPS1 3 Publications Verification	SHP2 SHP1 Phosphatase	Cardiovascular Disease Cancer
PHPS1 is a potent and selective Shp2 inhibitor with K_is of 0.73, 5.8, 10.7, 5.8, and 0.47 μM for Shp2, Shp2-R362K, Shp1, PTP1B, and PTP1B-Q, respectively .

HY-B1357

Digitoxin 5+ Cited Publications	Bcl-2 Family Caspase Apoptosis HSV Na+/K+ ATPase Calcium Channel	Cardiovascular Disease Cancer
Digitoxin is an anti-cancer agent. Digitoxin induces apoptosis, inhibits influenza cytokine storm, causes DNA double-stranded breaks (DSBs) and blocks the cell cycle at the G2/M phase. Digitoxin induces calcium uptake into cells by forming transmembrane calcium channels and can be used for research of heart failure .

HY-N2263

Skimmin 1 Publications Verification Umbelliferone glucoside	Interleukin Related TGF-β Receptor TNF Receptor Parasite	Inflammation/Immunology
Skimmin (Umbelliferone glucoside) is a major pharmacologically active and orally active molecule present in Hydrangea paniculata, a medical herb used in traditional Chinese medicine as an anti-inflammatory agent. Skimmin has renal protective activity. Skimmin can improve creatinine clearance, and reduce plasma creatinine, and kidney injuries. Skimmin has good anti-amoebic activity against the HM1:IMMS strain of Entamoeba histolytica. Skimmin has anti-cancer and neuroprotective activities. Skimmin reduces cardiac fibrosis as well as decreasing TNF-α, IL-6, IL1β, and TGFβ1 in cardiac tissues. Skimmin can be studied in research for diabetes and diabetes-related diseases .

HY-137605

WSF1-IN-1	Transmembrane Glycoprotein	Cancer
WSF1-IN-1 (compound 136), an orally active WSF1 inhibitor, can be used in the study for WSF1 (Wolfram syndrome) related tumors, with IC₅₀ values of 0.33 μM and >27 μM in HepG2 parental and HepG2 WFS1 KO cell lines, respectively .

HY-169480

Lipid C2	Liposome	Infection Cancer
Lipid C2 is an ionizable cationic lipid that has been used in the formation of lipid nanoparticles (LNP) for mRNA delivery in vivo. LNPs containing Lipid C2 and encapsulating an mRNA reporter selectively accumulate in the liver and spleen but not the heart, lungs, or kidneys in mice. LNP containing Lipid C2 and encapsulating mRNA encoding the Epstein-Barr virus (EBV) protein latent membrane protein 2 (LMP-2), in combination with an anti-programmed cell death protein 1 (PD-1) antibody, decrease tumor volume and reverse T cell exhaustion, as well as increase the percentage of CD3 ⁺CD8 ⁺ central and CD3 ⁺CD8 ⁺ effector memory T cells and decrease the percentage of CD3 ⁺ T cells expressing Pd-1, in the spleen in a CT26 murine EBV-infected colon cancer model .

HY-136379

CID44216842 2 Publications Verification Cdc42-IN-1	Ras	Cancer
CID44216842 (Cdc42-IN-1) is a potent Cdc42-selective guanine nucleotide binding lead inhibitor. The EC₅₀s for Cdc42 WT and Cdc42Q61L mutant are 1.0 and 1.2 μM in GTP binding assay, respectively. The EC₅₀s for Cdc42 WT and Cdc42Q61L mutant are 0.3 and 0.5 μM in GDP binding assay, respectively. Use as a molecular probe .

HY-Y0966

Glycine 5+ Cited Publications	Endogenous Metabolite iGluR VEGFR	Neurological Disease
Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is orally active. Glycine can be used to study cell protection, cancer, neurological diseases, and angiogenesis .

HY-Y0966R

Glycine (Standard)	Reference Standards Endogenous Metabolite iGluR VEGFR	Neurological Disease
Glycine (Standard) is the analytical standard of Glycine. This product is intended for research and analytical applications. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is orally active. Glycine can be used to study cell protection, cancer, neurological diseases, and angiogenesis .

Cat. No.	Product Name

HY-L018

TGF-beta/Smad Compound Library

340 compounds

The transforming growth factor beta (TGF-β) signaling pathway is involved in many cellular processes in both the adult organism and the developing embryo including cell growth, cell differentiation, apoptosis, cellular homeostasis and other cellular functions. The TGF-β superfamily comprises TGF-βs, bone morphogenetic proteins (BMPs), activins and related proteins. Signaling begins with the binding of a TGF beta superfamily ligand to a TGF beta type II receptor. The type II receptor is a serine/threonine receptor kinase, which catalyzes the phosphorylation of the Type I receptor. The type I receptor then phosphorylates receptor-regulated SMADs (R-SMADs) which can now bind the coSMAD (e.g. SMAD4). R-SMAD/coSMAD complexes accumulate in the nucleus where they act as transcription factors and participate in the regulation of target gene expression. Deregulation of TGF-β signaling contributes to developmental defects and human diseases, including cancers, some bone diseases, chronic kidney disease, etc.

MCE designs a unique collection of 340 TGF-beta/Smad signaling pathway compounds. TGF-beta/Smad Compound Library acts as a useful tool for TGF-beta/Smad-related drug screening and disease research.

Cat. No.	Product Name

HY-K6126

*Human Kidney* Cancer Organoid Kit**
MCE Human Kidney Cancer Organoid Kit includes a basic culture medium for Kidney Cancer organoids, as well as culture supplements, and is designed for the effective construction of human Kidney Cancer organoids.

Cat. No.	Product Name	Target	Research Area

HY-P99020

Fresolimumab 1 Publications Verification GC1008	TGF-beta/Smad	Metabolic Disease Inflammation/Immunology Cancer
Fresolimumab (GC1008) is a human monoclonal antibody against TGF-β that neutralizes all mammalian active subtypes of TGF-β. The binding affinity of Fresolimumab to TGF-β2 is 1.8 nM. Fresolimumab improves Bleomycin (HY-108345)-induced acute lung injury. Fresolimumab radiolabeled with ⁸⁹Zr can be used for PET analysis of TGF-β expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease .

HY-P991565

CE-355621	c-Met/HGFR	Cancer
CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. CE-355621 can effectively bind with human c-Met (K_D = 200 pM, IC₅₀ = 466 pM) in A549 cells and cyno c-Met (K_D = 610 pM) in cynomolgus kidney cells. CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding. CE-355621 significantly inhibit the growth of tumors dependent on the c-Met/HGF pathway. CE-355621 can be used for research on cancer such as glioblastoma and gastric cancer .

Cat. No.	Product Name	Chemical Structure

HY-W654256

Matrine-d3

Matrine-d₃ (Matridin-d₃) is a deuterium labeled Matrine (HY-N0164). Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus that can act as a kappa opioid receptor and u-receptor agonist. Matrine has a variety of pharmacological effects, including anti-cancer, anti-oxidative stress, anti-inflammation and anti-apoptosis effects. Matrine is potential in the research of disease like human non-small cell lung cancer, hepatoma, papillary thyroid cancer and acute kidney injury (AKI) .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P85834

	Mucin 1 Antibody (YA5526) ADMCKD; ADMCKD1; Breast carcinoma associated antigen DF3; Breast carcinoma-associated antigen DF3; CA 15-3; CA15 3; CA15 3 antigen; CA15-3; CA15.3; cancer antigen 15-3; Carcinoma associated mucin; Carcinoma-associated mucin; CD 227; CD227; DF3 antigen; EMA; Episialin; Epithelial Membrane Antigen; H23 antigen; H23AG; KL 6; KL-6; KL6; Krebs von den Lungen-6; MAM 6; MAM6; MCD; MCKD; MCKD1; Medullary cystic kidney disease 1; autosomal dominant; Medullary cystic kidney disease, autosomal dominant; MUC 1; MUC-1; MUC-1/SEC; MUC-1/X; MUC1; MUC1-alpha; MUC1-beta; MUC1-CT; MUC1-NT; MUC1/ZD; MUC1_HUMAN; Mucin 1; Mucin 1 cell surface associated; Mucin 1 transmembrane; Mucin 1, cell surface associated; Mucin-1 subunit beta; Peanut reactive urinary mucin; Peanut-reactive urinary mucin; PEM; PEMT; Polymorphic epithelial mucin; PUM; Tumor associated epithelial membrane antigen; Tumor associated epithelial mucin; Tumor associated mucin; Tumor-associated epithelial membrane antigen; Tumor-associated mucin	IHC-P, WB, ICC/IF, ELISA	Human
	Mucin 1 Antibody (YA5526) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Mucin 1. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification